Bruno Daniele, MD, director, Department of Oncology and Medical Oncology, G. Rummo Hospital, Italy, discusses the significance of the RESORCE trial, which examined the use of regorafenib (Stivarga) as a treatment for patients with hepatocellular carcinoma (HCC).
